PBPH: Portfolio Building Block World Pharma and Biotech Index ETF
What this ETF is trying to do
The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) is designed to give investors exposure to the global pharmaceutical and biotechnology industries. It holds a variety of companies that develop medicines and healthcare technologies.
What the numbers show
As of October 5, 2026, the share price for PBPH was $27.75.
Looking at the performance so far this year (Year-to-Date), the ETF has a price return of approximately 9.92%. The supplied total return for the same period is also 9.92%. Price return measures only the change in the share price, while total return includes other factors like distributions.
Data for one-year and three-year returns was not supplied.
Top Holdings
The ETF holds 55 different assets. As of October 7, 2026, the top holdings included:
• Eli Lilly and Co: 15.31%
• Johnson & Johnson: 10.00%
• AbbVie Inc: 7.25%
• Merck & Co Inc: 5.62%
• Roche Holding AG: 4.65%
• AstraZeneca PLC: 4.61%
• Amgen Inc: 4.39%
• Novartis AG: 4.10%
• Gilead Sciences Inc: 3.96%
• Pfizer Inc: 3.48%
These holdings can change over time.
Income and distribution explanation
PBPH has a distribution yield of approximately 0.08%. This describes the cash distributions relative to the ETF price. Over the last 12 months, it has made one payout. The distribution frequency is listed as irregular or less frequent.
It is important for new investors to remember that a distribution yield is not the same as a total return. A high yield alone can be misleading because it does not guarantee that the original investment value is being preserved.
NAV erosion explanation
"NAV erosion" happens when the net asset value of a fund declines over time. This is a risk that income investors watch closely because they want their principal investment to stay stable.
For this ETF, the severe erosion-risk flag is false. However, the erosion score is currently unavailable because there is not enough verified price history to calculate it.
Pros
• Positive year-to-date price and total returns of 9.92%.
• Provides exposure to many large, well-known global healthcare companies.
Cons
• Very low distribution yield (0.08%).
• Irregular payout schedule.
• Limited historical data available for long-term performance.
Beginner takeaway
PBPH is a fund focused on the world's pharmacy and biotech companies. While it has shown growth so far this year, it provides very little cash income to investors. Because it lacks a long price history, there is not enough data to provide a formal erosion-risk score.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | ELI LILLY AND CO | LLY | 15.31% |
| 2 | JOHNSON & JOHNSON | JNJ | 10.00% |
| 3 | ABBVIE INC | ABBV | 7.25% |
| 4 | MERCK & CO INC | MRK | 5.62% |
| 5 | ROCHE HOLDING AG ORDINARY SHARES NEW | n/a | 4.65% |
| 6 | ASTRAZENECA PLC | AZN:XLON | 4.61% |
| 7 | AMGEN INC | AMGN | 4.39% |
| 8 | NOVARTIS AG REGISTERED SHARES | n/a | 4.10% |
| 9 | GILEAD SCIENCES INC | GILD | 3.96% |
| 10 | PFIZER INC | PFE | 3.48% |